Baseline Characteristics of Patients
| Value in dose group* | ||||
| Characteristic | 4 GBq | 6 GBq | 7.4 GBq | 9.3 GBq |
| Age (y) | ||||
| Median | 75.5 | 70.5 | 70.5 | 73.5 |
| Range | 57–85 | 66–79 | 58–85 | 67–78 |
| Gleason score | ||||
| Median | 8 | 8 | 9 | 8 |
| 7 | 4 | 2 | 0 | 4 |
| 8 | 2 | 3 | 3 | 1 |
| 9 | 3 | 3 | 6 | 3 |
| Unknown | 1 | 2 | 1 | 1 |
| Initial PSA level (ng/mL) | ||||
| Median | 83 | 61 | 107 | 92 |
| Range | 2.4–2,801 | 1.2–387 | 12.9–1,176 | 48.5–626.2 |
| WBCs (/nL) | ||||
| Mean | 6.4 | 6.8 | 5.8 | 6.5 |
| SD | 3.2 | 3.4 | 2.3 | 2.3 |
| Platelets (/nL) | ||||
| Mean | 235.3 | 221.8 | 241.4 | 204.7 |
| SD | 83.2 | 70.6 | 81.0 | 47.6 |
| Alkaline phosphatase level (U/L) | ||||
| Mean | 138.8 | 131.7 | 252.5 | 202.1 |
| SD | 77.1 | 60.1 | 217.5 | 345.4 |
| Hemoglobin level (g/dL) | ||||
| Mean | 11.8 | 11.9 | 11.0 | 11.4 |
| SD | 2.4 | 1.5 | 2.1 | 1.7 |
| Localization of metastases | ||||
| Lymph node | 5 | 5 | 8 | 9 |
| Bone | 9 | 9 | 9 | 7 |
| Liver | 0 | 1 | 1 | 1 |
| Lung | 2 | 3 | 1 | 2 |
| Brain | 1 | 0 | 0 | 0 |
| Other | 3 | 2 | 3 | 0 |
| Local recurrence | 0 | 1 | 1 | 0 |
| Previous therapy | ||||
| RPx | 9 | 8 | 5 | 4 |
| LRTx | 5 | 6 | 6 | 3 |
| CRPC | 10 | 10 | 10 | 10 |
| Abiraterone | 4 | 6 | 8 | 8 |
| Enzalutamide | 3 | 2 | 7 | 10 |
| Bisphosphonates | 2 | 0 | 1 | 3 |
| Denosumab | 2 | 1 | 2 | 4 |
| 223Ra | 1 | 3 | 0 | 3 |
| Taxane | 4 | 4 | 5 | 8 |
| Total dose (GBq)† | 10.1 ± 4.8 | 13.3 ± 5.1 | 18.5 ± 3.9 | 25.4 ± 4.3 |